Listar por autor "Luque, Gloria"
Mostrando ítems 1-11 de 11
-
DQB1*0602 allele shows a strong association with multiple sclerosis in patients in Malaga, Spain.
Fernández-Fernández, Óscar; Fernández, Victoria; Alonso, Antonio; Caballero-González, Abelardo
; Luque, Gloria; Bravo, Mariano; León-Martín, Antonio; Mayorga Mayorga, Cristobalina; Leyva-Fernández, Laura; De Ramón Garrido, Enrique[et al.] (Springer, 2004-04)
Background The human leukocyte antigen (HLA) class II DR2 haplotype (DRB1*1501, DQA1*0102, DQB1*0602) has been associated with multiple sclerosis (MS) in all ethnic groups and very strongly in Caucasians. Aim To investigate ... -
Gene expression in IFNß signalling pathway differs between monocytes, CD4 and CD8 T cells from MS patients
Oliver-Martos, Begoña; Órpez, Teresa; Pinto-Medel, Maria Jesús; Mayorga Mayorga, Cristobalina; García-León, Juan Antonio; Maldonado-Sanchez, Rafael; Suardíaz García, Margarita; Guerrero, Miguel; Luque, Gloria; Leyva-Fernández, Laura; Fernández Fernández, Óscar[et al.] (Elsevier, 2011)
IFNß exerts its activity through the interaction with IFNAR, through activation of the JAK/STAT pathway. We analyzed the changes in IFNAR1, IFNAR2, STAT1, STAT2, Tyk2, JAK1, IRF9 and MxA gene expressions after prolonged ... -
IFNAR1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-beta treatment response
Leyva-Fernández, Laura; Fernández Fernández, Óscar; Fedetz, María; Blanco, Eva; Fernández Sánchez, Victoria Eugenia; Oliver-Martos, Begoña; León, Antonio; Pinto-Medel, María-Jesús; Mayorga Mayorga, Cristobalina; Guerrero, Miguel; Luque, Gloria; Alcina, Antonio; Matesanz, Fuencisla[et al.] (Elsevier, 2005)
We investigated the role of three polymorphisms in the IFNAR1 (SNPs 18417 and -408) and IFNAR2 (SNP 11876) genes in multiple sclerosis (MS) susceptibility and in the IFNbeta treatment response in a group of 147 patients ... -
IFNAR1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-beta treatment response.
Leyva-Fernández, Laura; Fernández-Fernández, Óscar; Fedetz, María; Blanco, Eva; Fernández, Victoria E.; Oliver-Martos, Begoña; León, Antonio; Pinto-Medel, María Jesús; Mayorga Mayorga, Cristobalina; Guerrero, Miguel; Luque, Gloria; Alcina, Antonio; Matesanz, Fuencisla[et al.] (Elsevier, 2005-04-22)
We investigated the role of three polymorphisms in the IFNAR1 (SNPs 18417 and -408) and IFNAR2 (SNP 11876) genes in multiple sclerosis (MS) susceptibility and in the IFNβ treatment response in a group of 147 patients and ... -
Interferon receptor expression in multiple sclerosis patients
Oliver-Martos, Begoña; Mayorga Mayorga, Cristobalina; Leyva-Fernández, Laura; León, Antonio; Luque, Gloria; C Lopez, Juan; Tamayo, Jose A; Pinto-Medel, Maria Jesús; De Ramón, Enrique; Blanco, Eva; Alonso, Ana; Fernández Fernández, Óscar[et al.] (Elsevier, 2006)
To determine the gene expression of IFNAR1, IFNAR2 and MxA protein and the association with IFNbeta treatment response in MS patients. MS patients treated with IFNbeta had a significant decrease in IFNAR1 and IFNAR2 ... -
Kinetics and incidence of anti-natalizumab antibodies in multiple sclerosis patients on treatment for 18 months
Oliver-Martos, Begoña; Fernández Fernández, Óscar; Órpez, Teresa; Alvarenga, Marcos Papais; Pinto-Medel, Mª Jesús; Guerrero, Miguel; León, Antonio; López-Madrona, José Carlos; Maldonado-Sánchez, Rafael; García-León, Juan Antonio; Luque, Gloria; Fernández Sánchez, Victoria Eugenia; Leyva-Fernández, Laura[et al.] (SAGE Journals, 2011)
Natalizumab is a monoclonal antibody shown to be highly effective in the treatment of relapsing–remitting multiple sclerosis (RRMS). Patients treated with natalizumab can develop antibodies directed against this agent that ... -
Kinetics and incidence of anti-natalizumab antibodies in multiple sclerosis patients on treatment for 18 months.
Oliver-Martos, Begoña; Fernández, Óscar; Orpez, Teresa; Alvarenga, Marco Papais; Pinto-Medel, María Jesús; Guerrero, Miguel; León, Antonio; López-Madrona, José Carlos; Maldonado-Sánchez, Rafael; García-León, Juan Antonio; Luque, Gloria; Fernández, Victoria; Leyva-Fernández, Laura[et al.] (SAGE, 2011-03)
Natalizumab is a monoclonal antibody shown to be highly effective in the treatment of relapsing-remitting multiple sclerosis (RRMS). Patients treated with natalizumab can develop antibodies directed against this agent that ... -
Neutralizing antibodies against IFN beta in patients with multiple sclerosis: a comparative study of two cytopathic effect tests (CPE) for their detection
Oliver-Martos, Begoña; Orpez, Teresa; Mayorga Mayorga, Cristobalina; Leyva-Fernández, Laura; López-Gómez, Carlos; Marín, Carmen; Luque, Gloria; Fernández Fernández, Óscar[et al.] (Elsevier, 2009)
The purpose of this study is to monitor the development of anti-natalizumab antibodies to evaluate their first appearance in multiple sclerosis patients, since their presence has been associated with a reduction in the ... -
Study of binding and neutralising antibodies to interferon-β in two groups of relapsing-remitting multiple sclerosis patients.
Fernández Fernández, Óscar; Mayorga Mayorga, Cristobalina; Luque, Gloria; Guerrero, Miguel; Guerrero, Rocío; Leyva-Fernández, Laura; León-Martín, Antonio; Blanca, Miguel[et al.] (Springer Nature, 2001)
Interferon (IFN)-β is generally considered an effective treatment for multiple sclerosis (MS); however, some patients do not respond to this therapy, possibly due to the production of neutralising antibodies (NAB) which ... -
The CD4+ T-cell subset lacking expression of the CD28 costimulatory molecule is expanded and shows a higher activation state in multiple sclerosis.
Pinto-Medel, María Jesús; García-León, Juan Antonio; Oliver-Martos, Begoña; López-Gómez, Carlos; Luque, Gloria; Arnáiz-Urrutia, Carlos; Órpez, Teresa; Marín-Bañasco, Carmen; Fernández Fernández, Óscar; Leyva-Fernández, Laura[et al.] (Elsevier, 2012-01-18)
Multiple sclerosis (MS) is a chronic debilitating disease, in which T-cells are considered to play a pivotal role. CD28 is the quintessential costimulatory molecule on T-cells and its expression declines progressively ... -
The efficacy of natalizumab in patients with multiple sclerosis according to level of disability: results of an observational study.
Fernández Fernández, Óscar; Papais Alvarenga, Marcos; Guerrero, Miguel; León, Antonio; Alonso, Ana; López-Madrona, Jose Carlos; Leyva-Fernández, Laura; Oliver-Martos, Begoña; De Ramón, Enrique; Luque, Gloria; Fernández, Victoria[et al.] (Sage Publications, 2010-11-18)
Background: Little is known about how the level of disability at the start of treatment with natalizumab affects its efficacy. Objectives: The aim of this study was to investigate the effect of natalizumab on relapses in ...